Results 271 to 280 of about 1,097,021 (302)
Some of the next articles are maybe not open access.

Checkpoint inhibitors in pancreatic cancer

Cancer Treatment Reviews, 2019
Immune checkpoint inhibitors, targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathways have shown remarkable potential in several types of cancer. In this review we summarize published and ongoing studies on checkpoint inhibitors in pancreatic cancer ...
Andreas Henriksen   +3 more
openaire   +2 more sources

Checkpoint Inhibitor–Induced Colitis

American Journal of Gastroenterology, 2020
Immune checkpoint inhibitors have revolutionized treatment and overall survival for several different types of cancer. Antibodies to cytotoxic T-lymphocyte-associated protein 4 and to programmed cell death protein 1 and its ligand enhance cytotoxic T-cell survival, thus augmenting antitumor action and consequently inducing immune-related adverse events,
Emanuelle, Bellaguarda, Stephen, Hanauer
openaire   +2 more sources

Cardiotoxicity of Immune Checkpoint Inhibitors

Current Treatment Options in Cardiovascular Medicine, 2019
Immunotherapies, particularly immune checkpoint inhibitors (ICI), are revolutionary cancer therapies being increasingly applied to a broader range of cancers. Our understanding of the mechanism, epidemiology, diagnosis, and treatment of cardiotoxicity related to immunotherapies remains limited.
Lili, Zhang   +8 more
openaire   +2 more sources

Checkpoint inhibitors go viral

Nature Biotechnology, 2019
As clinical evidence mounts demonstrating the power of combining oncolytic viruses and checkpoint inhibitors, companies are scrambling to get in on the action.
openaire   +2 more sources

Melanoma and Immune Checkpoint Inhibitors

Current Oncology Reports, 2018
Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients.
Masutaka, Furue   +5 more
openaire   +2 more sources

Immune Checkpoint Inhibitors in Cholangiocarcinoma

Immunotherapy, 2023
Cholangiocarcinoma is an epithelial malignancy originating in the biliary tracts and frequently recurs even with surgical resection. Unresectable disease has a 5-year overall survival of less than 10%. Given this poor prognosis, additional therapies are urgently needed. Chemotherapy has been the mainstay of treatment for many years.
openaire   +2 more sources

The Clinical Landscape of HDAC Inhibitors

Medical Epigenetics, 2021
Arasu Ganesan
exaly  

Therapeutics and DNA Methylation Inhibitors

Medical Epigenetics, 2021
Shyamala C Navada
exaly  

Home - About - Disclaimer - Privacy